| ISIN | LU2851597687 |
|---|---|
| Valor Number | 136503229 |
| Bloomberg Global ID | |
| Fund Name | Swisscanto (LU) Equity Fund Sustainable Healthy Longevity NT CHF |
| Fund Provider |
Swisscanto Fondsleitung AG
Zurich E-Mail: fonds@swisscanto.ch |
| Fund Provider | Swisscanto Fondsleitung AG |
| Representative in Switzerland | Swisscanto Fondsleitung AG |
| Distributor(s) | Schweizerische Kantonalbanken |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | The total commitments of the fund may not amount to more than 210% as a result of the use of derivatives (max. 100%) and temporary borrowing (max. 10%). |
| Peculiarities |
| Current Price * | 96.08 CHF | 20.11.2025 |
|---|---|---|
| Previous Price * | 96.00 CHF | 19.11.2025 |
| 52 Week High * | 105.52 CHF | 30.01.2025 |
| 52 Week Low * | 87.20 CHF | 11.04.2025 |
| NAV * | 96.08 CHF | 20.11.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 84,065,152 | |
| Unit/Share Assets *** | 58,229,920 | |
| Trading Information SIX | ||
| YTD Performance | -2.82% |
31.12.2024 - 20.11.2025
31.12.2024 20.11.2025 |
|---|---|---|
| 1 month | +4.41% |
20.10.2025 - 20.11.2025
20.10.2025 20.11.2025 |
| 3 months | +4.37% |
20.08.2025 - 20.11.2025
20.08.2025 20.11.2025 |
| 6 months | +2.56% |
20.05.2025 - 20.11.2025
20.05.2025 20.11.2025 |
| 1 year | -3.52% |
20.11.2024 - 20.11.2025
20.11.2024 20.11.2025 |
| 2 years | -3.92% |
27.08.2024 - 20.11.2025
27.08.2024 20.11.2025 |
| 3 years | - | - |
| 5 years | - | - |
| Equity Participation Rate in % | 87.32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Johnson & Johnson | 3.96% | |
|---|---|---|
| Pfizer Inc | 3.76% | |
| Edwards Lifesciences Corp | 3.45% | |
| Thermo Fisher Scientific Inc | 3.41% | |
| IQVIA Holdings Inc | 3.32% | |
| Boston Scientific Corp | 2.92% | |
| AstraZeneca PLC | 2.87% | |
| Eli Lilly and Co | 2.78% | |
| CVS Health Corp | 2.76% | |
| Halma PLC | 2.68% | |
| Last data update | 31.10.2025 | |
| TER | 0.01% |
|---|---|
| TER date | 31.03.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 0.00% |
| Ongoing Charges *** | 0.01% |
|
SRRI ***
|
|
| SRRI date *** | 31.10.2025 |